These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18060247)

  • 1. [Helping antibodies. Targeted antithrombotic and fibrinolytic therapy].
    Schwarz M; Hagemeyer CE; Peter K; Bode C
    Hamostaseologie; 2007 Dec; 27(5):360-2. PubMed ID: 18060247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-chain antibodies as new antithrombotic drugs.
    Hagemeyer CE; Schwarz M; Peter K
    Semin Thromb Hemost; 2007 Mar; 33(2):185-95. PubMed ID: 17340468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GP IIb/IIIa blockade during peripheral artery interventions.
    Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
    Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
    Stoll P; Bassler N; Hagemeyer CE; Eisenhardt SU; Chen YC; Schmidt R; Schwarz M; Ahrens I; Katagiri Y; Pannen B; Bode C; Peter K
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1206-12. PubMed ID: 17322097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in pharmacotherapy of thrombosis.
    Labuzek K; Krysiak R; Okopien B; Herman ZS
    Pol J Pharmacol; 2003; 55(4):523-33. PubMed ID: 14581710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trends in antithrombotic drug and device development.
    Fareed J
    Semin Thromb Hemost; 1996; 22 Suppl 1():3-8. PubMed ID: 8807721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [From the physiopathology of thrombosis to therapeutic targets].
    Nurden P; Ndoko S; Nurden AT
    Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1210-7. PubMed ID: 11794961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanisms and indicators of thrombogenesis after heart valve replacement].
    Scharf RE; Giers G
    Z Kardiol; 1998; 87 Suppl 4():7-19. PubMed ID: 9857462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?
    Hohmann JD; Wang X; Krajewski S; Selan C; Haller CA; Straub A; Chaikof EL; Nandurkar HH; Hagemeyer CE; Peter K
    Blood; 2013 Apr; 121(16):3067-75. PubMed ID: 23380744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-chain antibodies as diagnostic tools and therapeutic agents.
    Hagemeyer CE; von Zur Muhlen C; von Elverfeldt D; Peter K
    Thromb Haemost; 2009 Jun; 101(6):1012-9. PubMed ID: 19492141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
    Chew DP; Huang Z; Pieper KS; White H; Mahaffey KW; Ferguson JJ; Califf RM; Aylward PG
    Am Heart J; 2008 Feb; 155(2):239-44. PubMed ID: 18215592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and risk.
    Freudenberger RS; Fuster V
    Mt Sinai J Med; 1996; 63(5-6):342-58. PubMed ID: 8898540
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiplatelet agents and arterial thrombosis.
    Billett HH
    Cardiol Clin; 2008 May; 26(2):189-201, vi. PubMed ID: 18406994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons.
    Fontayne A; Meiring M; Lamprecht S; Roodt J; Demarsin E; Barbeaux P; Deckmyn H
    Thromb Haemost; 2008 Oct; 100(4):670-7. PubMed ID: 18841291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Various therapy options. Medical Chemistry of platelet aggregation inhibitors].
    Zettl H; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2009; 38(4):314-9. PubMed ID: 19572349
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted antithrombotic protein micelles.
    Kim W; Haller C; Dai E; Wang X; Hagemeyer CE; Liu DR; Peter K; Chaikof EL
    Angew Chem Int Ed Engl; 2015 Jan; 54(5):1461-5. PubMed ID: 25504546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic and antiplatelet therapies in relation to risk stratification in patients with non-ST elevation acute coronary syndrome: insights from the Sino-Global Registry of Acute Coronary Events.
    Zhang LJ; Chen YD; Song XT; Zhao FH; Lü SZ
    Chin Med J (Engl); 2009 Mar; 122(5):502-8. PubMed ID: 19323898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-active drugs : the relationships among dose, effectiveness, and side effects.
    Patrono C; Coller B; Dalen JE; FitzGerald GA; Fuster V; Gent M; Hirsh J; Roth G
    Chest; 2001 Jan; 119(1 Suppl):39S-63S. PubMed ID: 11157642
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological and mechanical revascularization strategies in STEMI: integration of the two approaches.
    Pollack C
    J Invasive Cardiol; 2008 May; 20(5):231-8. PubMed ID: 18460708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review: Nutriceuticals as antithrombotic agents.
    Chakrabarti S; Freedman JE
    Cardiovasc Ther; 2010 Aug; 28(4):227-35. PubMed ID: 20553290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.